Hiroaki Wakiyama
Overview
Explore the profile of Hiroaki Wakiyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
522
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakashima T, Matsumoto K, Yoshitake T, Wakiyama H, Hisano O, Uehara R, et al.
Jpn J Radiol
. 2023 Aug;
42(1):96-101.
PMID: 37587315
Purpose: This study evaluated the efficacy and safety of transvaginal approach combined intracavitary and interstitial brachytherapy (IC/IS BT) assisted by transrectal ultrasound (TRUS) for treatment of locally advanced cervical cancer...
2.
Fukushima H, Furusawa A, Kato T, Wakiyama H, Takao S, Okuyama S, et al.
Mol Cancer Ther
. 2023 Jul;
22(10):1215-1227.
PMID: 37461129
IL15 is a potent inducer of differentiation and proliferation of CD8+ T and natural killer (NK) cells, making it a promising candidate for cancer immunotherapy. However, limited efficacy of systemic...
3.
Kato T, Riahin C, Furusawa A, Fukushima H, Wakiyama H, Okuyama S, et al.
Nanomedicine (Lond)
. 2023 May;
18(8):659-666.
PMID: 37254845
Evaluation of lymphatic drainage can be challenging to differentiate between separate drainage basins because only one 'color' is typically employed in sentinel node studies. This study aimed to test the...
4.
Kitagawa A, Osawa T, Noda M, Kobayashi Y, Aki S, Nakano Y, et al.
Br J Cancer
. 2023 Apr;
128(12):2206-2217.
PMID: 37076565
Background: Driver alterations may represent novel candidates for driver gene-guided therapy; however, intrahepatic cholangiocarcinoma (ICC) with multiple genomic aberrations makes them intractable. Therefore, the pathogenesis and metabolic changes of ICC...
5.
Inagaki F, Wakiyama H, Furusawa A, Okada R, Kato T, Fujimura D, et al.
Biomed Pharmacother
. 2023 Feb;
160:114390.
PMID: 36791566
The bones are a common site for metastasis arising from solid tumors such as breast and prostate cancer. Chemotherapy, including immunotherapy, is rarely curative. Radiotherapy with pain palliation can temporize...
6.
Kato T, Fukushima H, Furusawa A, Okada R, Wakiyama H, Furumoto H, et al.
Oncoimmunology
. 2022 Dec;
11(1):2152248.
PMID: 36465486
The immune system is recognized as an important factor in regulating the development, progression, and metastasis of cancer. Myeloid-derived suppressor cells (MDSCs) are a major immune-suppressive cell type by interfering...
7.
Wakiyama H, Kato T, Furusawa A, Choyke P, Kobayashi H
Nanophotonics
. 2022 Nov;
10(12):3135-3151.
PMID: 36405499
Near-infrared photoimmunotherapy (NIR-PIT) is a new cancer treatment that uses an antibody-photo-absorber conjugate (APC) composed of a targeting monoclonal antibody conjugated with a photoactivatable phthalocyanine-derivative dye, IRDye700DX (IR700). APCs injected...
8.
Inagaki F, Kato T, Furusawa A, Okada R, Wakiyama H, Furumoto H, et al.
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297471
Disialoganglioside (GD2) is a subtype of glycolipids that is highly expressed in tumors of neuroectodermal origins, such as neuroblastoma and osteosarcoma. Its limited expression in normal tissues makes GD2 a...
9.
Kato T, Furusawa A, Okada R, Inagaki F, Wakiyama H, Furumoto H, et al.
Mol Cancer Ther
. 2022 Oct;
22(1):75-88.
PMID: 36223542
Near-infrared photoimmunotherapy (NIR-PIT) is a new cancer treatment that uses an antibody-IRDye700DX (IR700) conjugate that binds to a target followed by the application of NIR light that results in dramatic...
10.
Wakiyama H, Kato T, Furusawa A, Okada R, Inagaki F, Furumoto H, et al.
Cancer Immunol Res
. 2022 Sep;
10(11):1386-1397.
PMID: 36169564
Programmed cell death 1 (PD-1) blockade therapy can result in dramatic responses in some patients with cancer. However, about 15% of patients receiving PD-1 blockade therapy experience rapid tumor progression,...